Tags

Type your tag names separated by a space and hit enter

Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects.
BMC Anesthesiol. 2014; 14:53.BA

Abstract

BACKGROUND

This study compared efficacy and safety of the selective relaxant binding agent sugammadex (2 mg/kg) with neostigmine (50 μg/kg) for neuromuscular blockade (NMB) reversal in Chinese and Caucasian subjects.

METHODS

This was a randomized, active-controlled, multicenter, safety-assessor-blinded study (NCT00825812) in American Society of Anesthesiologists Class 1-3 subjects undergoing surgery with propofol anesthesia. Rocuronium 0.6 mg/kg was administered for endotracheal intubation, with 0.1-0.2 mg/kg maintenance doses given as required. NMB was monitored using TOF-Watch(®) SX. At second twitch reappearance, after last rocuronium dose, subjects received sugammadex 2 mg/kg or neostigmine 50 μg/kg plus atropine 10-20 μg/kg, according to randomization. Primary efficacy variable was time from sugammadex/neostigmine to recovery of the train-of-four (TOF) ratio to 0.9.

RESULTS

Overall, 230 Chinese subjects (sugammadex, n = 119, neostigmine, n = 111); and 59 Caucasian subjects (sugammadex, n = 29, neostigmine, n = 30) had evaluable data. Geometric mean (95% CI) time to recovery to TOF ratio 0.9 was 1.6 (1.5-1.7) min with sugammadex vs 9.1 (8.0-10.3) min with neostigmine in Chinese subjects. Corresponding times for Caucasian subjects were 1.4 (1.3-1.5) min and 6.7 (5.5-8.0) min, respectively. Sugammadex 2 mg/kg was generally well tolerated, with no serious adverse events reported. There was no residual NMB or recurrence of NMB.

CONCLUSION

Both Chinese and Caucasian subjects recovered from NMB significantly faster after sugammadex 2 mg/kg vs neostigmine 50 μg/kg, with a ~5.7 times (p < 0.0001) faster recovery with sugammadex vs neostigmine in Chinese subjects. Sugammadex was generally well tolerated.

TRIAL REGISTRATION

ClinicalTrials.gov Identifier: NCT00825812.

Authors+Show Affiliations

Peking University First Hospital, No 8 Xishiku St, Beijing 100034, China.Department of Anaesthesiology, Vejle Hospital, Vejle, Denmark.West China Hospital, Sichuan University, Chengdu, China.Department of Anesthesiology, University Hospitals Leuven, Leuven, Belgium.Union Hospital, Tongji Medical College, Wuhan, China.Anaesthesia and Intensive Care, Asker and Baerum Hospital, Oslo, Norway.Department of Anesthesiology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.Department of Anaesthesia, Hillerød Hospital, Hillerød, Denmark.Beijing Chaoyang Hospital, Beijing, China.Peking Union Medical College Hospital, Beijing, China.MSD, Oss, The Netherlands.MSD, Oss, The Netherlands.Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA.

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25187755

Citation

Wu, Xinmin, et al. "Rocuronium Blockade Reversal With Sugammadex Vs. Neostigmine: Randomized Study in Chinese and Caucasian Subjects." BMC Anesthesiology, vol. 14, 2014, p. 53.
Wu X, Oerding H, Liu J, et al. Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiol. 2014;14:53.
Wu, X., Oerding, H., Liu, J., Vanacker, B., Yao, S., Dahl, V., Xiong, L., Claudius, C., Yue, Y., Huang, Y., Abels, E., Rietbergen, H., & Woo, T. (2014). Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiology, 14, 53. https://doi.org/10.1186/1471-2253-14-53
Wu X, et al. Rocuronium Blockade Reversal With Sugammadex Vs. Neostigmine: Randomized Study in Chinese and Caucasian Subjects. BMC Anesthesiol. 2014;14:53. PubMed PMID: 25187755.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. AU - Wu,Xinmin, AU - Oerding,Helle, AU - Liu,Jin, AU - Vanacker,Bernard, AU - Yao,Shanglong, AU - Dahl,Vegard, AU - Xiong,Lize, AU - Claudius,Casper, AU - Yue,Yun, AU - Huang,Yuguang, AU - Abels,Esther, AU - Rietbergen,Henk, AU - Woo,Tiffany, Y1 - 2014/07/12/ PY - 2014/01/17/received PY - 2014/06/26/accepted PY - 2014/9/5/entrez PY - 2014/9/5/pubmed PY - 2015/4/18/medline KW - Caucasian KW - Chinese KW - Neostigmine KW - Neuromuscular blockade KW - Rocuronium KW - Sugammadex SP - 53 EP - 53 JF - BMC anesthesiology JO - BMC Anesthesiol VL - 14 N2 - BACKGROUND: This study compared efficacy and safety of the selective relaxant binding agent sugammadex (2 mg/kg) with neostigmine (50 μg/kg) for neuromuscular blockade (NMB) reversal in Chinese and Caucasian subjects. METHODS: This was a randomized, active-controlled, multicenter, safety-assessor-blinded study (NCT00825812) in American Society of Anesthesiologists Class 1-3 subjects undergoing surgery with propofol anesthesia. Rocuronium 0.6 mg/kg was administered for endotracheal intubation, with 0.1-0.2 mg/kg maintenance doses given as required. NMB was monitored using TOF-Watch(®) SX. At second twitch reappearance, after last rocuronium dose, subjects received sugammadex 2 mg/kg or neostigmine 50 μg/kg plus atropine 10-20 μg/kg, according to randomization. Primary efficacy variable was time from sugammadex/neostigmine to recovery of the train-of-four (TOF) ratio to 0.9. RESULTS: Overall, 230 Chinese subjects (sugammadex, n = 119, neostigmine, n = 111); and 59 Caucasian subjects (sugammadex, n = 29, neostigmine, n = 30) had evaluable data. Geometric mean (95% CI) time to recovery to TOF ratio 0.9 was 1.6 (1.5-1.7) min with sugammadex vs 9.1 (8.0-10.3) min with neostigmine in Chinese subjects. Corresponding times for Caucasian subjects were 1.4 (1.3-1.5) min and 6.7 (5.5-8.0) min, respectively. Sugammadex 2 mg/kg was generally well tolerated, with no serious adverse events reported. There was no residual NMB or recurrence of NMB. CONCLUSION: Both Chinese and Caucasian subjects recovered from NMB significantly faster after sugammadex 2 mg/kg vs neostigmine 50 μg/kg, with a ~5.7 times (p < 0.0001) faster recovery with sugammadex vs neostigmine in Chinese subjects. Sugammadex was generally well tolerated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00825812. SN - 1471-2253 UR - https://www.unboundmedicine.com/medline/citation/25187755/Rocuronium_blockade_reversal_with_sugammadex_vs__neostigmine:_randomized_study_in_Chinese_and_Caucasian_subjects_ L2 - https://bmcanesthesiol.biomedcentral.com/articles/10.1186/1471-2253-14-53 DB - PRIME DP - Unbound Medicine ER -